Accessibility Menu
Gyre Therapeutics logo

Gyre Therapeutics

(NASDAQ) GYRE

Current Price$5.89
Market Cap$655.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-13%
5 Year+5%
1 Year-18%
1 Month-6%
Gyre Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 5.882026-07-20
Gyre Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.26%USD 6.342026-07-13
1 month-5.92%USD 6.252026-06-18
3 month-25.29%USD 7.872026-04-21
Year to date-16.71%USD 7.062025-12-31
1 year-18.45%USD 7.212025-07-18
3 year-9.47%USD 6.502023-07-21
5 year+4.96%USD 5.602021-07-21
Since inception-12.63%USD 6.732023-10-31

Gyre Therapeutics Financials at a Glance

Market Cap

$655.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$117.05M

Net Income (TTM)

-$6.29M

EPS (TTM)

-$0.08

P/E Ratio

-75.58

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$5.89

Volume

3

Open

$6.08

Previous Close

$5.88

Daily Range

$5.82 - $6.21

52-Week Range

$5.44 - $9.42

Estimated Earnings Date

Aug 10, 2026

GYRE News

No articles available.

GYRE: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Gyre Therapeutics

Gyre helps people suffering from serious organ scarring and chronic swelling. The company makes medicines to treat lung and liver diseases. Its treatments reach patients in both China and the United States.

Fighting Organ Scarring

  • ETUARY: An anti-fibrotic drug used to treat idiopathic pulmonary fibrosis, a condition where lung tissue becomes scarred and stiff.
  • Etorel: A soft capsule therapy for lung scarring and other interstitial lung diseases that affect breathing.
  • Contiva: A tablet used to treat low blood platelet levels in adults who have chronic liver disease.
  • Hydronidone: A lead development candidate for liver fibrosis currently undergoing late-stage clinical trials in China and the US.

Recent Moves and Mergers

  • Entered a merger agreement with Cullgen Inc. on March 2, 2026, to expand its biotechnology research.
  • Completed a business combination on October 30, 2023, to acquire a controlling interest in Gyre Pharmaceuticals.
  • Partnered with Jiangsu Wangao Pharmaceuticals in May 2024 to obtain the drug registration for Etorel.
  • Launched Contiva in the China market in March 2025 to expand its liver-related product portfolio.

Two Regions, One Goal

Gyre maintains a dual presence with headquarters in San Diego and a commercial infrastructure in China. The company holds 18 global patents and manages a clinical pipeline targeting high-need inflammatory conditions.

How the Numbers Look

  • Revenue reached $37.2 million in Q4 2025, up 33.4% from $27.9 million in Q4 2024.
  • Gross profit rose to $35.5 million in Q4 2025, a 32.8% increase over the prior year.
  • Operating income dropped to $120,000 in Q4 2025, down 79.9% from $597,000 in Q4 2024.
  • Net loss deepened to $1.7 million in Q4 2025, worsening from $99,000 in Q4 2024.

Bottom Line

Gyre has transitioned from a development-stage firm to a commercial biopharmaceutical company with revenue-generating products. The business uses its current sales in China to support the clinical development of new fibrosis therapies.

AI Generated • May 4, 2026

Industry

Biotechnology

Sector

Health Care

Employees

625

CEO

Ping Zhang, MBA

Website

www.gyretx.com

Headquarters

San Diego, CA 92130, US

GYRE Financials

Key Financial Metrics (TTM)

Gross Margin

95.09%

Operating Margin

-0.12%

Net Income Margin

-5.37%

Return on Equity

-6.27%

Return on Capital

10.74%

Return on Assets

-3.88%

Earnings Yield

-1.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$655.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

111.49M

Volume

3

Avg. Volume

94.39K

Financials (TTM)

Gross Profit

$111.30M

Operating Income

-$139.00K

EBITDA

$3.16M

Operating Cash Flow

$4.32M

Capital Expenditure

-$1.28M

Free Cash Flow

$3.04M

Cash & ST Invst.

$49.81M

Total Debt

$823.00K

Gyre Therapeutics Performance Analysis

Gyre Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 102,290,0001294.0%
20232023-12-31USD 113,450,00010.9%
20242024-12-31USD 105,757,000-6.8%
20252025-12-31USD 116,588,00010.2%
Gyre Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3021.4%
Q32025-09-3014.2%
Q42025-12-3121.7%
Q12026-03-31-39.5%
Gyre Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.46N/A
20232023-12-31USD -1.41N/A
20242024-12-31USD 0.05N/A
20252025-12-31USD 0.02-53.2%
Gyre Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-48.8%
Q32025-09-301486.4%
Q42025-12-31-147.9%
Q12026-03-31-498.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$22.52M

+2.1%

Gross Profit

$21.29M

+0.6%

Gross Margin

94.55%

N/A

Market Cap

$655.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.05M

N/A

Employees

625

N/A

Net Income

-$8.62M

-419.3%

EBITDA

-$8.57M

-265.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$49.81M

+66.6%

Total Debt

$823.00K

-48.1%

Accounts Receivable

$26.81M

+19.1%

Inventory

$11.35M

+44.1%

Long Term Debt

$72.00K

-90.8%

Short Term Debt

$751.00K

-6.7%

Return on Assets

-3.88%

N/A

Return on Invested Capital

-0.10%

N/A

Free Cash Flow

$3.00M

+416.0%

Operating Cash Flow

$3.18M

+2565.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTMXCytomX Therapeutics, Inc.
$3.52-2.76%
KROSKeros Therapeutics, Inc.
$10.61-0.28%
AVXLAnavex Life Sciences Corp.
$2.42+1.26%
MGTXMeiraGTx Holdings plc
$12.21-1.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZYBTZhengye Biotechnology
$8.01+10.48%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$28.31+0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.68-0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.65+0.00%

Questions About GYRE

What is the current price of Gyre Therapeutics?

Gyre Therapeutics is trading at $5.88 per share.

What is the 52-week range for Gyre Therapeutics?

Over the past 52 weeks, Gyre Therapeutics has traded between $5.44 and $9.42.

How much debt does Gyre Therapeutics have?

As of the most recent reporting period, Gyre Therapeutics reported total debt of $823.00K.

How much cash does Gyre Therapeutics have on hand?

Gyre Therapeutics reported $37.50M in cash and cash equivalents in its most recent financial results.

What is Gyre Therapeutics’s dividend yield?

Gyre Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services